Levosimendan reduces myocardial damage and improves cardiodynamics in streptozotocin induced diabetic cardiomyopathy via SERCA2a/NCX1 pathway. [electronic resource]
Producer: 20170227Description: 55-65 p. digitalISSN:- 1879-0631
- Animals
- Body Weight
- Cardiomyopathies -- drug therapy
- Cardiotonic Agents -- therapeutic use
- Diabetes Mellitus, Experimental -- complications
- Heart -- drug effects
- Hemodynamics
- Hydrazones -- therapeutic use
- Male
- Natriuretic Peptide, Brain -- metabolism
- Nitric Oxide -- metabolism
- Pyridazines -- therapeutic use
- Rats
- Rats, Wistar
- Sarcoplasmic Reticulum Calcium-Transporting ATPases -- metabolism
- Simendan
- Sodium-Calcium Exchanger -- metabolism
- Streptozocin
- Transforming Growth Factor beta -- metabolism
- Troponin I -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.